Path2Dx^TM is a Digital Pathology and rapid annotation platform supported by Board and Platform Certified Pathologists across all major tumor types. It links all commercially available molecular pathology platforms with a CE-IVD 2 hour ISO15189 certifiable process for integration with common laboratory practices. It is intended to support three principle objectives: 1) to align and integrate with Molecular Pathology techniques, platforms and devices; 2) as an educational forum for pathological review; 3) to support the Groups expanding portfolio of IOS and DNARD signature panels. The platform is supporting the ISO15189 Annotation phase of EQA activities of the EMQN through an unrestricted educational donation. The platform will support schemes and educational content for annotation, educational activities for interpretation of select stains and other pathology based biomarkers. Path2Dx^TM offers laboratories and diagnostic sites a rapid certified platform for digital annotation of solid tumor biopsies proposed for subsequent genetic analysis. One of the most challenging issues with solid tumor biopsies is the volume and quality of neoplastic cells for molecular diagnostic procedures. In order to advance this stage in the diagnostic workflow, BMS has developed a propriety platform (device and IT) supported by a Team of Board Certified Pathologists to offer 24/7/365 rapid (<2h) digital annotations for solid tumor biopsies entering specified molecular procedures.